SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a potential takeover bid for eBay, fueling intense community speculation about the firm's strategic direction and financing. Discussions among retail investors are sharply divided between excitement over a potential monumental transformation and skepticism regarding the viability of such a large-scale acquisition.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a Wall Street Journal report that GameStop is building a stake in the company ahead of a potential takeover bid. Community discussion is heavily focused on the financial feasibility of such an acquisition given the significant market cap disparity between the two companies, with some investors dismissing the rumors as pure speculation while others express excitement over the potential for a massive retail transformation.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The community is actively debating the legitimacy of the MULN crypto token, with many users drawing parallels between its price action and the volatile history of its associated EV stock. Conversations are heavily polarized, featuring aggressive recruitment attempts from supporters hoping for a speculative pump alongside vocal detractors labeling the project a recurring scam.

IDEX

IDEX is generating significant buzz as community members discuss a potential short squeeze and a bullish breakout, fueled by optimism surrounding the protocol's upcoming liquidity initiatives and platform growth. Investors are actively debating whether the token is poised for an exponential run to higher resistance levels or if current volatility reflects a recurring pump-and-dump cycle.

WorldFinancial

World Liberty Financial is facing intense scrutiny and community backlash following a proposed governance vote to implement a multi-year token lockup, fueling ongoing debates about transparency and management's handling of the project. Investors remain sharply divided, with some betting on a recovery through upcoming supply shocks and token burns, while others label the project a scam amid concerns over insider selling and legal challenges from prominent industry figures.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is surging as investors pivot toward its emerging pharmaceutical and advanced materials manufacturing capabilities, which are being positioned as a strategic domestic solution amid tightening import tariffs. The stock is seeing heavy retail and institutional interest as the community speculates on impending contract awards and potential shifts in the company's long-term growth trajectory.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors rally behind its strategic partnership with Nvidia and Meta to power data centers with small modular reactors, fueling optimism about its long-term AI-driven growth trajectory. Community discussions are highly polarized, balancing excitement over these major technology alliances and DOE milestones against skepticism regarding the company's pre-revenue status and the volatility of its high-beta shares.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing active investor interest driven by a mix of steady defensive appeal and anticipation surrounding upcoming earnings. The community is focused on the company's long-term growth prospects in oncology and medical technology, alongside ongoing discussions about the impact of legal developments on corporate strategy.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is currently trending as investors debate whether the stock is significantly oversold following a sustained period of price consolidation and bearish sentiment. The community is focused on the upcoming earnings report as a potential catalyst, with active discussions weighing the impact of Pepsi's distribution partnership and the Alani Nu acquisition against broader concerns about channel inventory and margin compression.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is drawing significant community debate as investors weigh strong commercial launch signals for Tonmya against deep-seated frustration regarding recurring share dilution and requests for reverse split authorizations. While some bulls are encouraged by rising prescription trends and potential pipeline growth, others remain highly skeptical due to the company's historical capital management and the persistent impact on long-term shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>LCID remains under pressure from production scale challenges and persistent operating losses.</li><li>SNGX plunged after an independent panel recommended stopping its late-stage HyBryte trial in cutaneous T-cell lymphoma.</li><li>SRAD shares came under pressure after&nbsp;swinging to a Q1&nbsp;loss per share of 0.02 euros despite revenue growth.</li></ul>Shares of Lucid Group, Soligenix and Sportradar Group slid to fresh 52-week lows on Tuesday, with broader market weakness adding to pressure from a failed trial, weak results, and demand issues.On Tuesday,&nbsp;<a href="https://stocktwits.com/symbol/LCID">LCID stock</a> slipped 1%, marking its fifth straight session of losses, while&nbsp;<a href="https://stocktwits.com/symbol/SNGX">SNGX</a> plunged 70% and&nbsp;<a href="https://stocktwits.com/symbol/SRAD">SRAD</a> fell 11%.<h2 class="st-heading-2">Demand And Losses Weigh On LCID</h2>LCID shares extended their decline amid rising concerns over production-scale challenges and persistent operating losses in a volatile EV-demand environment.The company previously projected first-quarter revenue of about $280 million to $284 million, along with an operating loss of $1 billion, while full-year production guidance of 25,000 to 27,000 vehicles came in below earlier expectations. Investors remain focused on the company’s premium Air sedan and Gravity SUV lineup, with its lower-priced midsize platform not expected to enter production until later in 2026.Lucid is also seeking shareholder approval for several proposals at its June 4 annual meeting, including an amendment to its 2021 stock incentive plan that would add 23.5 million shares to the equity pool to support compensation for incoming CEO Silvio Napoli.Support from its largest shareholder, Saudi Arabia’s Public Investment Fund (PIF), remains key to the company’s financing. The sovereign wealth fund recently invested $550 million through its affiliate, Ayar Third Investment Company, as part of a broader $1.05 billion capital infusion that also included funding tied to a vehicle supply agreement with Uber and its autonomous mobility partner, Nuro.<h2 class="st-heading-2">Trial Setback Sends SNGX Tumbling</h2>SNGX stock plunged after an independent safety review panel recommended stopping a late-stage clinical trial of its cancer treatment, HyBryte, early, saying the interim results showed the therapy was unlikely to work as intended in patients with cutaneous T-cell lymphoma, a type of skin cancer.&nbsp;CEO Christopher J. Schaber said the company will now review the full dataset and may engage with regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to figure out potential next steps.With $5.9 million in cash on hand, the company said it is also evaluating options, including possible merger opportunities and advancing Dusquetide for Behcet’s Disease after receiving orphan drug designation from the European Commission.<h2 class="st-heading-2">Bleak Earnings Pressure SRAD Shares</h2>SRAD shares also came under pressure after the company reported first-quarter results showing a swing to a loss, even as revenue increased from the previous year.The sports data company reported a Q1 loss per share of 0.02 euros, compared with a loss per share of 0.07 euros a year earlier, while revenue rose to 346.5 million euros from 311.2 million euros a year ago. However, the company reiterated its full-year outlook for revenue of 1.56-1.58 billion euros and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of 390-400 million euros.The earnings call was followed by a price-target cut from Canaccord Genuity to $28 from $34, still implying a 127% upside from current levels. The brokerage also maintained its ‘Buy’ rating on SRAD shares. Separately, a short position disclosed by Muddy Waters Research added to investor caution after the firm raised concerns about exposure to illegal betting markets.<h2 class="st-heading-2">How Do Retail Traders Feel About LCID, SNGX, SRAD?</h2>Despite their fresh 52-week lows, retail sentiment for LCID, SNGX and SRAD remained broadly positive on Stocktwits, with LCID marked “extremely bullish” on ‘high’ message volume, while sentiment for SNGX and SRAD was “bullish” amid ‘extremely high’ chatter.Over the past year, LCID is down 77%, SNGX is down 80%, and SRAD is down 45%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-loses-orbit-ceo-pay-satellite-targets/cZBqnglRe3c">ASTS Stock Loses Orbit As Investors Get Cold Feet Over CEO Pay Tied To Satellite Targets&nbsp;</a>

Over the past year, LCID is down 77%, SNGX is down 80%, and SRAD is down 45%.

LCID, SNGX, SRAD Stock Hit 52-Week Lows Today: What's Driving The Selloff? 

On Tuesday, LCID stock slipped 1%, marking its fifth straight session of losses, while SNGX plunged 70% and SRAD fell 11%.

Equity

<ul class="summary-bullets"><li>The trial was evaluating HyBryte in a rare form of cancer with limited treatment options.</li><li>The company also plans to assess whether certain patient groups could still benefit from the therapy.</li><li>Last month, the European Commission granted orphan drug designation (ODD) to Soligenix’s Dusquetide for the treatment of Behçet’s Disease.</li></ul>Shares of Soligenix Inc. (SNGX) crashed more than 70% to a record low on Tuesday after the biotech firm said its late-stage trial to treat lymphoma suffered a severe blow after an independent committee recommended stopping the study due to a lack of effectiveness.<a href="https://stocktwits.com/symbol/SNGX">SNGX stock</a> recorded its biggest intraday loss in more than 14 years.<h2 class="st-heading-2">What Went Wrong?</h2>Soligenix said that an independent data monitoring committee recommended stopping the Phase 3 FLASH2 trial after an interim analysis showed the treatment was unlikely to be effective in patients with cutaneous T-cell lymphoma.The trial was evaluating HyBryte, a light-activated therapy, in a rare form of cancer with limited treatment options. Management said it will now review the full dataset to understand why the study fell short. The company also plans to assess whether certain patient groups could still benefit from the therapy.“We are obviously very disappointed with the unanticipated outcome of the study. Despite the fact that HyBryte demonstrated statistically significant reductions in CTCL lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study,” said Christopher J. Schaber, CEO of Soligenix.&nbsp;Depending on the findings, Soligenix said it may engage in discussions with regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to determine possible next steps.<h2 class="st-heading-2">Hopes Pinned On Behçet’s Disease Treatment</h2>Last month, the European Commission granted orphan drug designation (ODD) to Dusquetide for the treatment of Behçet’s Disease, following a positive recommendation from the EMA. Behçet’s Disease is a rare, chronic disorder that causes inflammation of blood vessels.The decision was supported by Phase 2a data showing the drug was effective and safe in patients. Orphan status in Europe gives the company up to 10 years of market exclusivity if the treatment is approved. The drug has already received orphan drug and fast track designations from the FDA.“With approximately $5.9 million of cash, we will evaluate all strategic options moving forward, including but not limited to merger and acquisition opportunities as well as the potential of advancing Dusquetide for the treatment of Behçet’s Disease, which demonstrated promising biological efficacy in a Phase 2 study last year using the intravenous formulation and has received orphan drug designation most recently from the EMA,” Schaber said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the massive sell-off, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has sunk 69% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbby-stock-pares-gains-hits-200dma-wedbush-price-target/cZB8yzPRedW">BBBY Stock Pares Early Gains Driven By Strong Q1 Report – Why Is Wedbush Optimistic About The Company’s Turnaround Story?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment

An independent committee recommended stopping Soligenix’s late-stage trial to treat lymphoma due to a lack of effectiveness.

Why Is Soligenix Stock Sinking Tuesday?

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.read more...

Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial...

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

By Christopher J. Schaber,&#160;chairman, president, and CEO,&#160;Soligenix; published via Clinical Leader&#160; Soligenix&#160;(NASDAQ: SNGX)&#160;is emphasizing&#160;the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that [&#8230;]

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent.&#160;Soligenix (NASDAQ: SNGX)&#160;has&#160;secured&#160;that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, [&#8230;]

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options.&#160;Soligenix (NASDAQ: SNGX)&#160;is demonstrating that momentum as it provides&#160; both an encouraging&#160;clinical update&#160;from its phase 3 FLASH2 study and positive comparative&#160;clinical results&#160;for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious [&#8230;]

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy Positive Clinical Results...

Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX)&#160;reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide [&#8230;]

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Current Price	$0.345
Prev Close	$0.345
Open	$0.3507
Dividend Yield	0.00%
50-Day Moving Average	$1.13
Beta	0.72
Avg. Volume	1.18M
PE Ratio	-0.13

52-Week High	$6.23
52-Week Low	$0.3157
Market Capitalization	$3.56M
EPS (Annual)	-$2.14
Price to Book	0.66
Revenue Per Employee	$0.00

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SNGX News

SNGXSoligenix Inc